DE69722858D1 - Intimale verdickungsinhibitoren - Google Patents

Intimale verdickungsinhibitoren

Info

Publication number
DE69722858D1
DE69722858D1 DE69722858T DE69722858T DE69722858D1 DE 69722858 D1 DE69722858 D1 DE 69722858D1 DE 69722858 T DE69722858 T DE 69722858T DE 69722858 T DE69722858 T DE 69722858T DE 69722858 D1 DE69722858 D1 DE 69722858D1
Authority
DE
Germany
Prior art keywords
group
substituted
halogen atom
amino
alkylaminoalkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69722858T
Other languages
English (en)
Other versions
DE69722858T2 (de
Inventor
Atsushi Sato
Tetsuji Asao
Yuichi Hagiwara
Makoto Kitade
Yasundo Yamazaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE69722858D1 publication Critical patent/DE69722858D1/de
Publication of DE69722858T2 publication Critical patent/DE69722858T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
DE69722858T 1996-01-17 1997-01-16 Intimale verdickungsinhibitoren Expired - Fee Related DE69722858T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP569396 1996-01-17
JP569396 1996-01-17
PCT/JP1997/000065 WO1997025986A1 (fr) 1996-01-17 1997-01-16 Inhibiteurs d'epaississement de l'intima

Publications (2)

Publication Number Publication Date
DE69722858D1 true DE69722858D1 (de) 2003-07-24
DE69722858T2 DE69722858T2 (de) 2004-05-13

Family

ID=11618190

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69722858T Expired - Fee Related DE69722858T2 (de) 1996-01-17 1997-01-16 Intimale verdickungsinhibitoren

Country Status (12)

Country Link
US (1) US5977130A (de)
EP (1) EP0815859B1 (de)
KR (1) KR100264807B1 (de)
AT (1) ATE243034T1 (de)
AU (1) AU708167B2 (de)
CA (1) CA2214759C (de)
DE (1) DE69722858T2 (de)
ES (1) ES2201266T3 (de)
HU (1) HUP9800757A3 (de)
NO (1) NO315688B1 (de)
RU (1) RU2145852C1 (de)
WO (1) WO1997025986A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6147106A (en) 1997-08-20 2000-11-14 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
US6906093B2 (en) 1995-06-07 2005-06-14 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6531502B1 (en) 1998-01-21 2003-03-11 Sugen, Inc. 3-Methylidenyl-2-indolinone modulators of protein kinase
US6828344B1 (en) * 1998-02-25 2004-12-07 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6569868B2 (en) 1998-04-16 2003-05-27 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
WO2000035921A1 (en) 1998-12-17 2000-06-22 F. Hoffmann-La Roche Ag 4,5-pyrazinoxindoles as protein kinase inhibitors
US6624171B1 (en) 1999-03-04 2003-09-23 Smithkline Beecham Corporation Substituted aza-oxindole derivatives
US6492398B1 (en) 1999-03-04 2002-12-10 Smithkline Beechman Corporation Thiazoloindolinone compounds
GB9904933D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
UA75054C2 (uk) * 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
US6620818B1 (en) 2000-03-01 2003-09-16 Smithkline Beecham Corporation Method for reducing the severity of side effects of chemotherapy and/or radiation therapy
TWI270545B (en) 2000-05-24 2007-01-11 Sugen Inc Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
US6706709B2 (en) 2000-06-02 2004-03-16 Sugen, Inc. Indolinone derivatives as protein kinase/phosphatase inhibitors
WO2002096361A2 (en) 2001-05-30 2002-12-05 Sugen, Inc. 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
CN1295216C (zh) * 2003-07-04 2007-01-17 中国人民解放军军事医学科学院毒物药物研究所 吲哚酮类衍生物及其用于制备抗肿瘤药物的用途
WO2005018531A2 (fr) * 2003-08-26 2005-03-03 'chemical Diversity Research Institute', Ltd. Compositions pharmaceutiques, composes azo-heterocycliques et procedes de fabrication et d'utilisation correspondants
WO2006105795A1 (en) * 2005-04-08 2006-10-12 Leo Pharma A/S Novel indolinone derivatives
WO2011032320A1 (en) 2009-09-21 2011-03-24 F. Hoffmann-La Roche Ag Novel alkene oxindole derivatives

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3413299A (en) * 1963-07-11 1968-11-26 Upjohn Co 3', 3'-di-substituted[spiro-indoline-3, 2'-oxiran]-2 ones and derivatives
US3428649A (en) * 1968-01-23 1969-02-18 Mcneilab Inc Oxindole derivatives
US3725403A (en) * 1970-10-20 1973-04-03 Squibb & Sons Inc Benzothiazine derivatives
US4002749A (en) * 1975-08-12 1977-01-11 E. R. Squibb & Sons, Inc. Substituted indolinones
JPS6229570A (ja) * 1985-07-29 1987-02-07 Kanegafuchi Chem Ind Co Ltd ３，５−ジイソプロピルベンジリデン複素環式化合物
ZA896851B (en) * 1988-09-14 1990-06-27 Hoffmann La Roche Use of ace-inhibitors
DK0429685T3 (da) * 1989-07-25 1997-12-15 Taiho Pharmaceutical Co Ltd Oxoindolderivat
WO1992007830A2 (en) * 1990-10-29 1992-05-14 Pfizer Inc. Oxindole peptide antagonists
JP3130342B2 (ja) * 1991-10-04 2001-01-31 日産化学工業株式会社 動脈硬化性血管内膜肥厚抑制薬
FR2694004B1 (fr) * 1992-07-21 1994-08-26 Adir Nouvelles 3-(Hydroxybenzylidényl)-indoline-2-ones et 3-(hydroxybenzylidényl)-indoline-2-thiones, leurs procédés de préparation, et les compositions pharmaceutiques qui les contiennent.
GB9313638D0 (en) * 1993-07-01 1993-08-18 Erba Carlo Spa Arylidene and heteroarylidene oxindole derivatives and process for their preparation
US5502072A (en) * 1993-11-26 1996-03-26 Pfizer Inc. Substituted oxindoles
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease

Also Published As

Publication number Publication date
DE69722858T2 (de) 2004-05-13
AU708167B2 (en) 1999-07-29
NO974280D0 (no) 1997-09-16
NO315688B1 (no) 2003-10-13
CA2214759A1 (en) 1997-07-24
CA2214759C (en) 2004-05-18
US5977130A (en) 1999-11-02
HUP9800757A3 (en) 1998-08-28
AU1398697A (en) 1997-08-11
EP0815859A4 (de) 2001-04-11
ATE243034T1 (de) 2003-07-15
ES2201266T3 (es) 2004-03-16
NO974280L (no) 1997-11-11
RU2145852C1 (ru) 2000-02-27
KR100264807B1 (ko) 2000-09-01
EP0815859A1 (de) 1998-01-07
WO1997025986A1 (fr) 1997-07-24
EP0815859B1 (de) 2003-06-18
HUP9800757A2 (hu) 1998-07-28
KR19980703023A (ko) 1998-09-05

Similar Documents

Publication Publication Date Title
DE69722858D1 (de) Intimale verdickungsinhibitoren
HRP20031098B1 (en) Beta-amino tetrahydroimidazo (1,2-a) pyrazines and tetrahydrotrioazolo (4,3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
HU9202265D0 (en) Wall-mounted disc for joining sanitary equipments onto mounting wall
MXPA03011522A (es) Derivados de naftil indol sustiduidos como inhibidores del tipo 1 del inhibidor del activador del plasmingeno.
DK0624584T3 (da) Piperazinderivater, der er nyttige som calmodulininhibitorer
NO168585C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrazolopyridiner
TW369533B (en) Quinoline compounds, process for preparing them and pharmaceutical composition containing them
DK0787726T3 (da) Ny forbindelse, fremgangsmåde til fremstilling deraf og antitumor-middel
EP1452528A4 (de) Xanthinoxidaseinhibitoren
AU2002221080A1 (en) Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparingthe same and use thereof
DK0618193T3 (da) Nitrogenholdige, bicycliske derivater som prolyl-endopeptidaseinhibitorer
NZ333550A (en) Matrix metalloproteinase inhibitors for inhibiting the release of TNF
AR002761A1 (es) Un compuesto derivado del triazol, su uso, una composicion farmaceutica que lo contiene, un metodo de tratamiento o prevencion de una infeccion fungica enun paciente humano mediante dicho compuesto o composicion, y procedimiento y compuestos intermedios para prepararlo.
DK1157998T3 (da) Heterocykliske forbindelser, mellemprodukter derfor og elastaseinhibitorer
EE04564B1 (et) Bifenlamidiini derivaadid, eelravim, vere koagulatsiooniinhibiitor ning proflaktiline ja terapeutiline toimeaine tromboosi v?i emboolia vastu
DE60034545D1 (de) Verwendung von chymase hemmern gegen vaskuläre lipidablagerung
DE69201596D1 (de) 7-Oxabicycloheptyl-substituierte, heterocyclische Amid-Prostaglandin-Analoge, verwendbar bei der Behandlung von vasospastischen und thrombotischen Krankheiten.
GB0119863D0 (en) DNA-PK inhibitors
DE69519182D1 (de) Azapeptid-Derivate
EP1201664A4 (de) Bemzimidazolverbindungen und medikamente die diese enthalten
ATE380028T1 (de) Mittel zur anregung des appetits und mittel zur behandlung von anorexie
EP1236735A4 (de) Benzamidin-derivate
NO20004679L (no) Farmasøytisk sammensetning inneholdende en cystein- proteasehemmer for forebygging og terapi av hjernevevsforringelse
DE60009301D1 (en) Benzimidazolverbindungen
TH41638A (th) อนุพันธ์ซัลโฟนิล

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee